







© World Health Organization 2019
Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO
licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). 
Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the
work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses
any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you
must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you
should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health
Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall
be the binding and authentic edition”. 
Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the
World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules).
Suggested citation. Medication Safety in Transitions of Care. Geneva: World Health Organization; 
2019 (WHO/UHC/SDS/2019.9). Licence: CC BY-NC-SA 3.0 IGO.
Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.
Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for
commercial use and  queries on rights and licensing, see http://www.who.int/about/licensing. 
Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures
or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from
the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests
solely with the user.
General disclaimers. The designations employed and the presentation of the material in this publication do not imply the
expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or
of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent
approximate border lines for which there may not yet be full agreement.
The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or
recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted,
the names of proprietary products are distinguished by initial capital letters.
All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the
published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the
interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use. 
Designed by CommonSense, Greece
Printed by the WHO Document Production Services, Geneva, Switzerland
3MEDICATION SAFETY IN TRANSITIONS OF CARE
Abbreviations .................................................................................................................................... 4
Preface .............................................................................................................................................. 5
Executive summary: medication safety in transitions of care........................................................ 9
1. Introduction.................................................................................................................................. 11
1.1 Transitions of care.................................................................................................................... 11
1.2 Medication reconciliation and review...................................................................................... 13
1.3 Medication-related harm........................................................................................................ 13
2. Why consider medication safety in transitions of care? .......................................................... 15
2.1 Prevalence of medication discrepancies at transitions of care .............................................. 16
2.2 Medication-related harm during transitions of care ................................................................ 17
2.3 Economic impact .................................................................................................................... 19
2.4 Limitations of the evidence base ............................................................................................ 19
3. What has been done to improve medication safety in transitions of care? ............................ 20
3.1 Engagement with patients, families and caregivers................................................................ 20
3.2 Medication reconciliation........................................................................................................ 23
3.3 Improvement in information quality and availability across transitions .................................. 26
3.4 Discharge and post-discharge interventions .......................................................................... 27
3.5 The economic case ................................................................................................................ 28
3.6 Challenges .............................................................................................................................. 28
4. What needs to be done .............................................................................................................. 30
4.1 Leadership commitment and planning.................................................................................... 30
4.2 Improvement programmes .................................................................................................... 30
4.3 Partnering with patients, families and caregivers .................................................................. 30
4.4 Medication reconciliation ........................................................................................................ 31
4.5 Information quality and availability at all care transitions ...................................................... 31
4.6 Building capacity of health care professionals ...................................................................... 32
4.7 Monitoring and measurement ................................................................................................ 33
5. Conclusions ................................................................................................................................ 35
References ...................................................................................................................................... 36
Annexes 
Annex 1. Glossary ............................................................................................................................ 43
Glossary references .......................................................................................................... 46
Annex 2. List of contributors............................................................................................................ 48
Contents
ACE angiotensin-converting enzyme
BPMH best possible medication history
CI confidence interval
EHR electronic health record
INN international nonproprietary name
IT information technology
LMIC low- and middle-income country
NSAID non-steroidal anti-inflammatory drug
OR odds ratio
WHO World Health Organization
4 MEDICATION SAFETY IN TRANSITIONS OF CARE
Abbreviations
5MEDICATION SAFETY IN TRANSITIONS OF CARE
Health care interventions are intended to
benefit patients, but they can also cause
harm. The complex combination of processes,
technologies and human interactions that
constitutes the modern health care delivery
system can bring significant benefits.
However, it also involves an inevitable risk of
patient harm that can – and too often does –
result in actual harm. A weak safety and
quality culture, flawed processes of care 
and disinterested leadership teams weaken
the ability of health care systems and
organizations to ensure the provision of safe
health care. Every year, a significant number
of patients are harmed or die because of
unsafe health care, resulting in a high public
health burden worldwide. 
Most of this harm is preventable. Adverse
events are now estimated to be the 14th leading
cause of morbidity and mortality in the world,
putting patient harm in the same league as
tuberculosis and malaria (1). The most important
challenge in the field of patient safety (see
Annex 1) is how to prevent harm, particularly
avoidable harm, to patients during their care.
Patient safety is one of the most important
components of health care delivery which is
essential to achieve universal health coverage
(UHC), and moving towards the UN Sustainable
Development Goals (SDGs). Extending health
care coverage must mean extending safe care,
as unsafe care increase costs, reduces
efficiency, and directly compromises health
outcomes and patient perceptions. It is
estimated that over half of all medicines are
Preface
prescribed, dispensed or sold inappropriately,
with many of these leading to preventable harm
(2). Given that medicines are the most common
therapeutic intervention, ensuring safe
medication use and having the processes in
place to improve medication safety (see Annex
1) should be considered of central importance
to countries working towards achieving UHC.
The Global Patient Safety Challenges of the
World Health Organization (WHO) shine a light
on a particular patient safety issue that poses a
significant risk to health. Front-line interventions
are then developed and, through partnership
with Member States, are disseminated and
implemented in countries. Each Challenge has
so far focused on an area that represents a
major and significant risk to patient health and
safety (see Annex 1). In 2005, the Organization,
working in partnership with the (then) World
Alliance for Patient Safety, launched the first
Global Patient Safety Challenge: Clean Care Is
Safer Care (3), followed a few years later by the
second Challenge: Safe Surgery Saves Lives
(4). Both Challenges aimed to gain worldwide
commitment and spark action to reduce health
care-associated infection and the risks
associated with surgery, respectively.
Recognizing the scale of avoidable harm 
linked with unsafe medication practices and
medication errors, WHO launched its third
Global Patient Safety Challenge: Medication
Without Harm in March 2017, with the goal 
of reducing severe, avoidable medication-
related harm by 50% over the next five years,
globally (5).
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Medication error: case scenario
Mrs Poly, a 65-year-old woman, came to the outpatient clinic complaining of abdominal pain and
dark stools. She had a heart attack five years ago. At her previous visit three weeks ago she was
complaining of muscle pain, which she developed while working on her farm. She was given a
non-steroidal anti-inflammatory drug (NSAID), diclofenac. Her other medications included aspirin,
and three medicines for her heart condition (simvastatin, a medicine to reduce her serum
cholesterol; enalapril, an angiotensin-converting enzyme (ACE) inhibitor; and atenolol, a beta
blocker). She was admitted to hospital as she developed symptoms of blood loss (such as
fatigue and dark stools). She was provisionally diagnosed as having a bleeding peptic ulcer due
to her NSAID, and her doctor discontinued diclofenac and prescribed omeprazole, a proton
pump inhibitor. Following her discharge, her son collected her prescribed medicines from the
pharmacy. Among the medicines, he noticed that omeprazole had been started and that all her
previous medicines had been dispensed, including the NSAID. As his mother was slightly
confused and could not remember exactly what the doctor had said, the son advised his mother
that she should take all the medications that had been supplied. After a week, her abdominal
pain continued and her son took her to the hospital. The clinic confirmed that the NSAID, which
should have been discontinued (deprescribed), had been continued by mistake. This time Mrs
Poly was given a medication list when she left the hospital which included all the medications
she needed to take and was advised about which medications had been discontinued and why.
This Challenge follows the same philosophy as
the previous Challenges, namely that errors are
not inevitable, but are very often provoked by
weak health systems, and so the challenge is to
reduce their frequency and impact by tackling
some of the inherent weaknesses in the system.
As part of the Challenge, WHO has asked
countries and key stakeholders to prioritize
three areas for strong commitment, early action
and effective management to protect patients
from harm while maximizing the benefit from
medication, namely:
• medication safety in high-risk situations
• medication safety in polypharmacy 
• medication safety in transitions of care.
Consider the following case scenario
describing a medication error (see Annex 1)
involving these three areas.
In this scenario the key steps that should have
been followed to ensure medication safety 
in the inpatient setting include:
1. Appropriate prescribing and risk
assessment
Medication safety should start with appropriate
prescribing and a thorough risk–benefit
analysis of each medicine is often the first step.
In this case scenario, prophylactic aspirin 
and NSAID without a gastroprotective agent 
left Mrs Poly at an increased risk of
gastrointestinal bleeding. NSAIDs can also
increase the risk of cardiovascular events,
which is of particular concern, as she had had 
a myocardial infarction (heart attack) five years
ago. This is a good example of a high-risk
situation requiring health care professionals 
to prescribe responsibly after analysing 
the risks and benefits.
2. Medication review
A comprehensive medication review (see
Annex 1) is a multidisciplinary activity whereby
the risks and benefits of each medicine are
considered with the patient and decisions
made about future therapy. It optimizes the use
of medicines for each individual patient.
Multiple morbidities usually require treatment
with multiple medications, a situation described
as polypharmacy (see Annex 1). Polypharmacy
can put the patient at risk of adverse drug
events (see Annex 1) and drug interactions
when not used appropriately. In this case, 
there should have been a review of
medications, particularly as Mrs Poly was
prescribed aspirin and diclofenac together. 
The haemodynamic changes following blood
loss should have also prompted temporary
stopping the ACE inhibitor before restarting once
the episode of blood loss has been resolved.
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The events leading to the error in this scenario and how these could have been prevented are
reflected in Figure 1, and the text below.






















3. Dispensing, preparation and
administration
This is a high-risk situation as the medication
(diclofenac) has the potential to cause harm.
However, this medication was continued after
discharge when the patient transitioned from
hospital to home. Dispensing this medicine and its
administration caused serious harm to Mrs Poly.
Dispensing this medicine and its administration
caused significant harm to Mrs Poly.
4. Communication and patient engagement
Proper communication between health care
providers and patients, and amongst health
care providers, is important in preventing
errors. When Mrs Poly was severely ill due to
gastric bleeding, the NSAID was discontinued.
However, the decision to discontinue the
medicine was not adequately communicated
either to the other health care professionals
(including the nurse or the pharmacist) or to
Mrs Poly. Initial presenting symptoms due to
adverse effects could have been identified
earlier if she had been warned about the risks.
5. Medication reconciliation at care
transitions
Medication reconciliation is the formal process
in which health care professionals partner 
with patients to ensure accurate and complete
medication information transfer at interfaces 
of care. Diclofenac, the NSAID that can cause
gastrointestinal bleeding and increase the risk
of cardiotoxicity and had led to this hospital
admission, was discontinued, and this
information should have been communicated 
at the time of discharge (in the form of a
medication list or patient-held medication
record). This would have helped her and her
caregivers in determining what the newly added
and discontinued medications needed to be.
Medication-related harm is harm caused to 
a patient due to failure in any of the various
steps of the medication use process or due 
to adverse drug reactions (see Annex 1 for
glossary). The relationship and overlap between
medication errors and adverse drug events 
is shown in Figure 2.
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Figure 2. Relationship between medication errors and adverse drug events 
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WHO is presenting a set of three technical
reports – Medication safety in high-risk
situations, Medication safety in polypharmacy,
and Medication safety in transitions of care – 
to facilitate early priority actions and planning
by countries and key stakeholders to address
each of these areas. The technical reports are
intended for all interested parties, particularly 
to inform national health policy-makers and
encourage appropriate action by ministries 
of health, health care administrators and
regulators, organizations, professionals,
patients, families and caregivers, and all who
aim to improve health care and patient safety.
This report – Medication safety in transitions 
of care – outlines the problem, current situation
and key strategies to reduce medication-related
harm in transitions of care. It should be
considered along with the companion 
technical reports on Medication safety 
in high-risk situations and Medication safety 
in polypharmacy.
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Unintended medication discrepancies 
affect nearly every patient that moves 
across transitions of care. The complex
challenge of improving medication safety
during transitions of care requires long-term
commitment from health care leaders and
cohesive efforts from health care professionals
to substantially reduce potential patient harm.
Each country participating in the Medication
Without Harm Challenge needs to give a clear,
long-term leadership commitment by defining
goals to improve medication safety at transition
points of care, developing a strategic plan with
short- and long-term objectives, and
establishing structures to ensure goals are
achieved. Countries need to put in place locally
relevant improvement programmes to develop,
test and implement effective solutions and
measure progress towards the goals.
The key strategies for improving medication
safety during transitions of care include:
• Implementing formal structured processes 
for medication reconciliation at all transition
points of care by (a) building the best
possible medication history (BPMH) by
interviewing the patient and verifying with 
at least one reliable information source; 
(b) reconciling and updating the medication
list; (c) communicating with the patient and 
future health care providers about changes 
in their medications, with agreed roles 
and responsibilities, training, support and
provision of tools and technology.
• Partnering between patients, families,
caregivers and health care professionals 
to agree on treatment plans, ensure patients
are equipped to manage their medications
safely, and ensure patients have an up-to-
date medication list.
• Where necessary, prioritizing patients 
at high risk of medication-related harm for
medication reconciliation and enhanced
support, for example pre- and post-discharge
contact.
• Implementing collaborative medication
management between medical, nursing 
and pharmacy personnel and, where staffing
is inadequate, planning and investing to
increase workforce capacity and capability,
including increasing availability and access 
to undergraduate and postgraduate
education and training.
• Improving the quality and availability 
of information at transitions of care and
identifying the most reliable information
sources for verifying medication histories 
at transitions. These could include 
patient-held medication record (medication
passport), information technology systems 
to facilitate reconciliation processes, 
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Introduction 1
1.1 Transitions of care
Transitions of care are the various points
where a patient moves to or returns from 
a particular physical location or makes
contact with a health care professional 
for the purposes of receiving health care 
(see Annex 1).
Transitions of care include movements of
patients between home, hospital, residential
care settings and consultations with different
health care providers. During transitions of
care, patients attend health care facilities 
where their medication may be reviewed 
and changed. This would include outpatient 
or primary care consultations with a health
care professional. Transitions of care may 
also refer to transitions requiring support 
from other care professionals, such as
caregivers at home, palliative care, social 
care or outreach services.
An example of the patient’s journey across
transitions of care and the medication use
processes involved is depicted in Figure 3.
































Source: Reproduced, with permission of the publisher, from Grimes T (7). 
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Some of the frequent transition points in health
care settings are:
• admission to hospital, community setting or
primary care, where a medication history is
taken, the inpatient prescription commenced
and medications are started, changed or
discontinued;
• transfer from one area within the hospital to
another, particularly where separate paper or
electronic medication records are kept, for
example emergency department to intensive
care unit, operating theatre to a clinical ward;
• referral from primary care setting to
secondary/tertiary care;
• discharge from hospital, where a discharge
prescription or instructions are issued; and
• transfer from one hospital to another hospital
or to a residential care setting, for example 
a nursing home or rehabilitation facility.
Figure 4. Changes in medication during transitions of care between home and hospital
1 Admission to hospital from home
2 Obtaining medication history
3 Verifying medication history using reliable source of medication information
4–7 Changes in medication during hospital stay
4 Medication reconciliation at admission
7 Medication reconciliation at discharge
8 Pre-discharge communication and patient engagement
9 Discharge from hospital to home
21 3 4 5 6 7 8 9
DAY 1 DAY 2 DAY 3 DAY 4
The points of transition within or across
healthcare settings are often associated 
with changes in medications that the patient
receives, depicted in Figure 4. 
In addition, patients’ medication may change
due to:
• starting, changing or discontinuing non-
prescription or over-the-counter medication
bought by the patient in pharmacies, retail
outlets or online;
• starting, changing or discontinuing herbal,
traditional or complementary medicines, 
with or without interaction with health care
professionals;
• using medications obtained from friends 
or family members;
• using medications obtained from unsafe
sources, including substandard and falsified
medications; and
• using substances, including alcohol 
and drugs, with the potential for abuse. 
Transitions of care do not include care
handover or handoff during staff transitions, 
for example at work shift changes. 
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Intentional discrepancies are the result 
of conscious decision-making by a patient 
or health care professional leading to the
change in medication history. Undocumented
intentional discrepancies are a failure to
document a conscious decision. Unintentional
discrepancies occur when no conscious
decision led to the change in medication
history. Undocumented intentional
discrepancies and unintentional discrepancies
may result in medication errors, which in turn
may lead to harm. Unintentional discrepancies
fall into two categories: omission (for example,
not prescribing a required medication) and
commission (for example, lack of patient
adherence, wrong dose or frequency, wrong
medication or failure to communicate the
reason for changes to medication therapy) (8).
Medication review is a structured evaluation
of patient‘s medicines with the aim of
optimizing medicines use and improving
health outcomes. This entails detecting 
drug related problems and recommending
interventions (see Annex 1).
Once medication reconciliation has been
performed to ascertain the medication the
patient has been taking, the medication 
review determines what the future treatment
plan should be, in light of the patient’s current
health and living conditions.
During comprehensive medication review 
the risks and benefits of each treatment are
considered and discussed with the patient 
and decisions made about future therapy. 
This may also occur at or after transition of
care, as well as in primary, residential, acute 
or outpatient settings.
1.3 Medication-related harm
The goal of WHO’s third Global Patient Safety
Challenge: Medication Without Harm is to
reduce severe, avoidable harm related to
medications by 50% over five years globally (5).
1.2 Medication reconciliation
and review
At each point in transitions of care, the
medication a patient was taking prior to the
transition needs to be identified. The best
possible medication history (BPMH, see 
Annex 1) may differ from what was prescribed
or dispensed and so the BPMH should be 
used to decide on the care required. At the 
next transition, the updated medication list 
and changes made to the BPMH should be
communicated to the patient and future health
care providers (Figure 3).
Medication reconciliation is the formal
process in which health care professionals
partner with patients to ensure accurate 
and complete medication information 
transfer at interfaces of care (see Annex 1).
Medication reconciliation consists of (7):
• Building the BPMH. The BPMH is obtained
by following a systematic process of
interviewing the patient, family or caregiver
and verifying the history with at least one
other reliable source of information to
determine the complete and correct list of the
patient’s actual medication use at the time of
the transition.
• Reconciling the BPMH with prescribed
medication. The BPMH is compared with
prescribed medication, discrepancies
identified and resolved (with or by the
prescriber) and changes documented, 
thus updating the medication list.
• Communicating accurate medication
information. Information on the list of current
medication and reasons for changes to the
previous list is provided to the patient, family
or caregiver and to health care providers to
whom care is being transferred.
Medication discrepancy refers to any
difference between the medication use
history and the admission medication orders.
Discrepancies may be intentional,
undocumented intentional or unintentional
discrepancies (see Annex 1). 
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Medication-related harm refers to patient
harm related to medication. It includes
preventable adverse drug events (e.g. 
due to a medication error or accidental 
or intentional misuse) and non-preventable
adverse drug events (e.g. an adverse drug
reaction) (see Annex 1).
Medication-related harm should be identified
and managed to optimize patient safety and
reported to pharmacovigilance (see Annex 1) 
or patient safety reporting systems, as
appropriate. The relationship and overlap
between medication errors and adverse drug
events is shown in Figure 2.
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Why consider medication 
safety in transitions of care? 2
Medication-related harm may also arise as 
a consequence of medication errors occurring
at a transition. Most patients admitted for
inpatient hospital care will experience at least
one medication discrepancy at one or more
transition points, which may result in harm
(Figure 5). Medication-related harm may also
cause or contribute to the need for a transition
in care, such as hospital admission.
Figure 5. Medication discrepancies at various transitions of care and frequency 
of medication-related harm 
14-98% of community-dwelling
older persons and 27-57% 
of those in residential aged 
care facilities had 
medication discrepancies (9)
25-80% of patients had 
at least one medication 






3-97% of adult patients (9) and 
22-72% of paediatric patients (10)
had at least one medication
discrepancy at admission
62% of patients had 
at least one unintentional 
medication discrepancy 
at transfer between units 
in hospital (11)
16 MEDICATION SAFETY IN TRANSITIONS OF CARE
2.1 Prevalence of medication
discrepancies at transitions 
of care
Estimating the prevalence of medication
discrepancies is challenging owing to variations
in the definitions, methods of detection and
classification systems used (12). A recent
Cochrane review pooled 20 studies and found
that 559 out of 1000 patients are at risk of
having one or more medication discrepancies
at transitions of care with standard health care
(13). These issues are illustrated by the widely
varying rates of discrepancies at transitions 
of care (9–11, 14–21). The available evidence
indicates that this is a global problem at
hospital admission, internal transfer, discharge
and other transition points. 
Discrepancies that are not identified and
resolved may place the patient at risk of
medication-related harm.
Hospital admission
Evidence identifies that most patients
experience at least one medication discrepancy
at hospital admission (14) and that this is 
a global issue. As illustrated below:
• 3.4–97% of adult patients (9) and 22–72.3%
of paediatric patients (10) had at least one
medication discrepancy on admission.
• A study conducted in Colombia, found 93.6%
of patients had at least one medication
discrepancy at admission with standard care,
including omission of all over-the-counter
medication (15).
• 77.5% of patients had one or more medication
discrepancy 24 hours after admission to 
a hospital in an Iranian study (16).
• 47% of patients in a Swedish hospital had 
at least one medication discrepancy (17).
• A mean of 1.72 medication discrepancies 
per patient was identified on admission 
to six hospitals in the United States 
of America (18).
Transfer within hospital
• According to a Canadian study, 62% of
patients had at least one unintentional
discrepancy during internal hospital 
transfer (11).
Discharge
• 25–80% of patients had at least one
medication discrepancy or failure to
communicate in-hospital medication 
changes at discharge (9).
• A national multi-site audit examined
discharge summaries in England and found
that 79% of patients had at least one new
medication started (with the reason
documented for approximately half of the
cases), 27% of patients had at least one
medication stopped (with the reason
documented for 57% of cases), and 23% 
of patients had at least one dose changed
(with a reason documented for 39% of
cases). Unintentional omissions of pre-
admission medication were noted for one
third of patients (19).
Community 
• 14.1–98.2% of patients had medication
discrepancies when medication reconciliation
was conducted in patients’ homes, in 
the primary care clinic prior to doctor
appointments or over the phone (9).
• A multi-site audit of certain hospitals in
England identified that intentional hospital
medication changes were not actioned 
in the primary care system within seven 
days of discharge for 13% of patients and 
at least one change was actioned incorrectly
for 6% of patients (19).
• Similarly, an Irish study identified that
discharge discrepancies persisted for 69%
of patients and 8% had additional errors 
in the 10–14 days post-discharge (20).
Residential aged care facilities
• 26.9–57.1% of patients had at least one
medication discrepancy between the
discharge summary and the residential aged
care facility medication list (9).
• A mean of 6.4 discrepancies per patient was
identified between the resident’s medication
orders before and after hospitalization during
medication reconciliation (21).
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Common types of discrepancies
There is diversity in the classifications of
discrepancy employed in studies investigating
medication safety at transitions of care. 
One systematic review identified omission 
of medication as the most common type 
of discrepancy. Other common types of
discrepancy at transitions of care are wrong
dose, interaction, contraindication, duplication)
and failure to communicate changes (12).
2.2 Medication-related harm during
transitions of care
Many discrepancies at transitions of care 
do not result in harm; however, a considerable
proportion of them do. For example, 
Salanitro et al. found 0.16 potentially harmful
discrepancies at admission and 0.3 at
discharge per patient (18). In a systematic
review between 11% and 59% of
discrepancies at admission and discharge
were considered to have potential for harm (14).
Medication-related harm is a frequent cause 
of or contributor to hospital admission:
• 6.5% of patients’ admissions to two acute
hospitals in the United Kingdom were related
to an adverse drug reaction, with the reaction
directly leading to an admission in 80% 
of cases (22).
• 8.8% of emergency admissions to an Irish
hospital were related to adverse drug events
(23), with an adverse drug event identified 
in 26% of emergency admissions in patients
aged over 65 years (24).
• 11.3% of patients aged 60 years or over had
an adverse drug event leading to admission,
and 46.2% of patients experienced one 
or more adverse drug events during
hospitalization in a Brazilian hospital. Risk
factors for adverse drug events included
multimorbidity (see Annex 1), number of
medications and use of medication considered
inappropriate for older patients (25).
Adverse drug events may not be identified 
or diagnosed in the course of routine clinical
screening and treatment, putting the patient at
greater risk of further harm. Early confirmation
of medication intake, and timely diagnosis 
and management of medication-related harm 
is necessary to minimize patient harm.
Reporting adverse drug events to the patient
safety incident reporting or pharmacovigilance
systems, as appropriate, is necessary to
facilitate learning at organizational, national 
and international level. It is acknowledged that
there is likely to be an underrecognition and
underreporting of medication-related harm 
in administrative health systems and databases
in general (26–28), when compared to research
studies quantifying rates of adverse drug
events. A study in England found that less than
1% of hospital admissions were due to adverse
drug reactions (29).In addition, in a study 
by Stausberg the prevalence of adverse drug
events in hospitals was found to be 3.22%
(3.20–3.23%) in England, 4.78% (4.73–4.83%)
in Germany, and 5.64% (5.63–5.66%) in the
United States of America (30). 
An individual patient’s risk of experiencing
medication-related harm, in any setting or in
transitions between care settings, increases
with the number of medicines (polypharmacy);
high-risk medications (see Annex 1); or in the
presence of morbidities (such as renal
impairment). Individuals with multimorbidity 
and those with continuous complex care
requirements may be particularly vulnerable 
to encounter adverse drug events associated
with suboptimal care across their multiple care
(31, 32). Multicenter medication reconciliation
quality improvement study (MARQUIS study)
estimated an average of 0.45 potentially
harmful medication discrepancies (either 
at admission or discharge) per patient in 
the United States of America (18). However, 
it is difficult to estimate the potentially harmful
discrepancies at admission and discharge 
and the number of harmed patients globally.
Harm from different types of medication
discrepancies can be severe for individual
patients, as in the examples below.
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Omission post-discharge. A man was changed
from warfarin to rivaroxaban (both
anticoagulants, to reduce the risk of stroke 
in patients with atrial fibrillation) in hospital. 
The discharge prescription was transcribed
onto the community prescribing system, 
but the anticoagulant was mistakenly omitted.
Two months later, the man suffered a stroke
and subsequently died.
Discharge prescribing error and delay in
identifying medication-related harm. A doctor
entered “LANZ” into an electronic system 
when wishing to prescribe lansoprazole (a
proton pump inhibitor to reduce stomach acid)
as a discharge medication, however incorrectly
selected olanzapine (an antipsychotic),
prescribing 30 mg (triple the usual starting dose
and 10 mg above the maximum licensed dose).
The patient became increasingly unwell, was
readmitted into hospital under a different team
and continued to deteriorate until a pharmacist
identified the error during medication
reconciliation. The patient took over 10 days 
to recover. The sequence of events leading 
to this error has been illustrated (Figure 6) 
in relation to the accident trajectory hypothesis
of error prevention as proposed by James
Reason, popularly known as the “Swiss cheese
model”.
Non-adherence: harm due to commission. 
A patient was admitted to hospital and his 
dose of methadone was confirmed with the
national treatment centre and with the patient.
On receiving his dose, the patient developed
extreme opioid toxicity, requiring reversal. 
The patient had not been taking his methadone
before admission, but had been selling it and
did not wish his health care provider to know
in case the dose would be reduced.
Lack of integrated care for physical and
mental health. A 75-year-old resident in 
a nursing home was admitted to hospital 
with lithium toxicity due to deteriorating renal
function. The physician discontinued the
patient’s lithium, resulting in a severe manic
episode. Consequently the psychiatrist
restarted lithium, as the reason for ceasing had
not been communicated across the health care
professional team. Lithium toxicity recurred,
lithium was discontinued and mania recurred.
Many months passed before treatment was
stabilized when the patient’s physical and
mental health needs were taken fully into
account.





Figure 6. Swiss cheese model as applied to medication-related harm




















































Medication discrepancies occurring at
transitions impact on health care systems 
in addition to the patient. This may include 
the use of substantial health care resources 
in treating patients, staff’s time in resolving
discrepancies, and resources spent towards
legal proceedings or claims due to negative
outcomes of health care. An estimated 15% 
of total hospital activity and expenditure is 
a direct outcome of adverse events in OECD
countries (34). The global cost of medication
errors has been estimated at US$ 42 billion
annually (35), with discrepancies and errors
occurring at transitions of care contributing 
to this figure.
2.4 Limitations of the evidence
base
Most studies that have quantified medication
discrepancies or harm associated with
medication use have been undertaken in 
high-income countries, with the majority
performed at admission to or discharge 
from hospital. Less evidence is available 
about medication safety at transitions of care 
in low- and middle-income countries (LMICs) 
or in other points of transitions of care.
However, the available evidence indicates 
that medication discrepancies may occur 
in LMICs (15, 16, 36) at least as frequently 
as in high-income countries (11, 17).
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Potential solutions to address medication
safety at transitions of care entail complex
health care interventions, involving people,
technology, systems and processes. As with
many complex interventions, the targeted
impact may be restricted by the prevailing
national and local health service structures 
and organizations, resource capacities and
capabilities (including human and technological
resources), and cultural settings. Although
many local, national and international initiatives
are worthy of inclusion in this section, 
the potential solutions described below 
are selected from systematic reviews and 
meta-analyses. Despite having limited
resources, some LMICs may still find these
potential solutions applicable.
3.1 Engagement with patients,
families and caregivers
Informed, knowledgeable and empowered
patients and families can contribute greatly to
their own positive health outcomes and safety,
including preventing, identifying and taking
early action to minimize harm associated 
with medication. Informed patients can
navigate self-medication and health choices
optimally (8, 37, 38). 
At transitions of care, partnership between
health care professionals and patients,
alongside families or caregivers is desirable.
The patient is the single constant in patient
care. Only the patient knows what medication
they are actually taking at the time of 
a transition (8). 
Informed patients and patient tools
Patient education, medication literacy and
appropriate use of tools can help patients 
in their medication management. These are
crucial to preventing medication-related harm
and improving medication safety at transitions
of care (38, 39). Two case studies of education
as a solution are presented below.
What has been done 
to improve medication safety 
in transitions of care?
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Case study: Education as a solution to prevent errors with refill prescription
A 60-year-old Ugandan woman went to the doctor and was given a refill prescription for her blood
pressure medication. She sent her grandson to the pharmacy to pick up the medicine.
Fortunately, the grandson had been given health literacy education at school and he was also
familiar with his grandmother’s usual prescription. Although the medication was not accompanied
by any printed information, the grandson immediately recognized that the dosing schedule on the
container – one tablet three times a day – was incorrect. It should have been one tablet daily.
Thanks to the vigilance of this young man, his grandmother did not take the excess doses of
medication, which would have posed a serious danger to her. In Uganda the topic of health
literacy is introduced in schools as a part of debates, music, dance and drama (40). Ugandan
patient safety advocate, Regina Kamoga of the Community Health and Information Network
(CHAIN) initiative says: “It is important to promote health literacy in schools because when
children acquire knowledge early in life, they are better placed to adopt a healthy lifestyle.”1
Case study: Improving knowledge and reducing misconceptions in a school-
based intervention
A secondary school-based educational intervention in Ecuador consisting of a lecture followed
by small working group seminars, improved knowledge and reduced misconceptions about
self-medication and appropriate medication use. The intervention continued to demonstrate
impact even after one year. Among the benefits were reductions in use of antidiarrhoeal
medicines, cough suppressants, common cold medication and multivitamins, and an improved
understanding of medication promotional activities (41).
There are multiple resources available 
to support engagement with patients for
enhancing safe medication use. Some 
selected examples of these are:
• A series of information sheets about health
literacy, its relevance to public policy, 
and the ways it can be used to promote 
good health is available in the WHO Health
literacy toolkit for low-and middle-income
countries (42).
• The Agency for Healthcare Research and
Quality has produced the AHRQ health
literacy universal precautions toolkit, 
with tools and resources highlighting self-
management and empowerment, spoken 
and written communication, and supportive
systems to promote better understanding 
of medications by adults and children (43).
Many information resources are available 
for patients on safe use of medication and
patient engagement to support decision
making in their treatment (44–48). Patient
information materials on safe medication use
(including discussing medication treatment
choice, response to medication, medication
adherence (see Annex 1) and asking questions
about the medication with healthcare
professions), reporting and prevention systems
of medication safety incidents, and how 
to keep track of medications, are available
internationally. 
1. Regina N. M. Kamoga, Community Health and Information Network, personal communication, 10 August 2017.
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Patient-held medication list
The first step in the medication reconciliation
process is to identify a patient’s medication list.
Patient knowledge and understanding about their
specific medication can be supported by the use
of a patient-held medication record or list. 
Medication lists held by or accessible 
to patients, in paper (e.g. medication card 
or medication passport) or electronic form 
(e.g. mobile application), can facilitate patients
to keep track of their medication and to share
details with health care providers (49).
Patient-held health or medication records are
particularly common in LMICs. Large patient
volumes, high health care professional
workloads and limited availability of information
technology (IT) contribute to limitations in, 
or absence of, organizationally stored patient
records. This has led to local, regional and
national systems where patients carry their
medication information (or all health information)
with them, bringing a booklet to healthcare
appointments and pharmacies. These systems
support ready access to the patient’s medication
list at health care interfaces. There is some
evidence of the positive effect of a patient
presenting a medication list at the time of
hospital admission on medication safety. For
example, Gleason et al. found that presenting
a medication list at hospital admission was
protective against medication error with 
potential to cause harm or to require intervention
or monitoring post-admission (50).
Many patients carry such a medication list with
them at all times for their own needs. On the
other hand, patients may not always carry a list
or have it with them at the point of clinical need
(either at scheduled care or acute admission).
Other pragmatic suggestions include taking 
a photo of the list, or of the medicines, on a
mobile phone, so that the information could be
readily available to the patient at all times.
Mobile applications and wearables devices 
can be utilized to assist patients in managing
their medication, by capturing and storing
medication-related data on platforms, which
can be remotely accessed by patients and
treating health care professionals. Many of
these mobile technologies have the potential
for additional functionality, including medication
adherence monitoring. Current development
efforts also focus on platforms that integrate
with patient’s health records and produce
mobile-accessible medication histories (51). 
An innovative example of how medical
information has been designed to be more
accessible includes the wearable device to
store digital vaccination records for women 
and children (52).
Provision of specific medication information 
Patients’ understanding of their specific
medications and how to use them can be aided
by:
• Affixing dispensing labels to the medicinal
product. It is a convention in many countries
to affix dispensing labels to the medicinal
product with product identification and
directions for use.
• Providing patient information leaflets.
Regulatory agencies sometimes require
patients to be provided with information
leaflets.
• Providing counselling or advice on use 
of tools to aid patient understanding.
Limitations in the availability of time of health
care professionals and other resources
required to effectively engage with patients
hinder the ability to consistently provide this
support. 
Support around discharge
A number of systematic reviews have been
undertaken on the topic of medication safety 
at transitions of care. One of the aspects
commonly identified in interventions as
supporting patient safety is communication
with the patient about discharge medication
and follow-up with the patient after discharge.
For example, Chukwuemeka Odumegwu
Ojukwu University Teaching Hospital in Nigeria
has a Drug Information Unit that supports
patients after discharge from hospital. All
medicine packets contain the unit’s phone
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number on which patients can call and ask
questions or discuss problems related to their
medication at any time.2 Another study
demonstrated that post-discharge follow-up
with a pharmacist reduced medication
discrepancies and improved patient knowledge
10–14 days after discharge (53). This illustrates
the potential benefit of providing support
around discharge to reduce potential harm 
at transitions of care.
3.2 Medication reconciliation
Medication reconciliation is a process that
facilitates transfer of accurate and complete
patient’s medication information at interfaces 
of care. Implementation of formal and
structured medication reconciliation processes
should include training of health care
professionals with agreed roles and
responsibilities of those involved. In addition,
it should provide appropriate tools and
technologies for the professionals to use.
The available evidence from major systematic
reviews and meta-analyses on medication
reconciliation indicate that a range of components
can assist medication reconciliation (54–56):
• medication reconciliation interventions with
pharmacy staff involvement and
multidisciplinary collaboration;
• interventions involving the patient, including
the use of patient-held medication lists or
medication passports (paper or electronic),
and communication between patients and
health care professionals;
• complex interventions to support discharge
and post-discharge support, particularly for
patients at high risk of adverse drug events;
and
• communication between providers, including
access to and interoperability of IT systems.
The ideal model is likely to involve a complex
intervention drawing on aspects of many of
these components. At each transition, patients
should be asked about their experience with
their medication. As outlined in section 2.2,
adverse drug events are a frequent cause 
of or contributor to hospital admission, yet
many of these reactions go unrecognized 
and remedial changes in medication therapy
are not made.
A systematic review of hospital-based
medication reconciliation on 26 controlled
studies identified that performing medication
reconciliation consistently reduced: 1)
medication discrepancies (17 of 17 studies), 
2) potential adverse drug events (5 of 6 studies)
and 3) adverse drug events (2 of 3 studies).
However, reduction in post-discharge health
care utilization (improvement in 2 of 8 studies)
was inconsistent. The interventions were
categorized under pharmacist-related, 
IT-focused and others, such as staff education
and use of a standardized medication
reconciliation tool. Key aspects of successful
interventions included intensive pharmacy staff
involvement and targeting the intervention 
to a high-risk patient population (54).
Although there is plenty of existing evidence 
to demonstrate the positive effect medication
reconciliation can have on identifying and
reducing the prevalence of medication
discrepancies and associated potential for
adverse drug events (9, 21, 39, 54, 55, 57–59),
there is also need to generate more evidence.
A recent Cochrane review of 20 studies also
emphasizes that more research on patient-level
outcomes (for instance, on hospitalization,
adverse drug events and healthcare utilization)
is required to fully evaluate the potential of
medication reconciliation as an intervention (13). 
2. Afam Udeozo, Chukwuemeka Odumegwu Ojukwu University Teaching Hospital, personal communication, 25 July
2017.
24 MEDICATION SAFETY IN TRANSITIONS OF CARE
Health workforce and skills mix
considerations for medication reconciliation
The skills and expertise of different health care
professionals should be utilized to improve
medication safety at transitions of care, with
collaboration and coordination to maximize
efficiency and effectiveness. 
A number of systematic reviews identified
pharmacist or pharmacy involvement in
medication reconciliation as being particularly
effective (54, 55) and finding it economically
attractive strategy for improving patient safety
in acute care (60). A systematic review and
meta-analysis concluded that pharmacy-led
medication reconciliation interventions at
either admission or discharge reduced
medication discrepancies (55). Feldman 
et al. showed that medication reconciliation
conducted in collaboration between nurses
and pharmacists potentially prevented patient
harm and was considered a cost–effective
intervention (61).
As part of the WHO High 5s Project, the same
protocol to determine BPMH following
emergency admission of patients aged 
65 years and over was implemented in 12
hospitals in the Netherlands. Unintentional
medication discrepancies reduced from 62% 
to 32% of patients with the pharmacy-based
model (odds ratio (OR) 0.16; 95% confidence
interval (CI) 0.12–0.21), however, there was 
no significant effect in hospitals where either 
a physician or a pharmacy technician obtained
the BPMH (increase from 53% to 62%; OR
1.45, CI 0.88–2.39) (57).
All United Kingdom medical schools require
final year medical students to complete a
prescribing safety assessment prior to
commencing clinical roles, providing a reliable
and consistent assessment of prescribing
competence (62).
Obtaining a medication history is an integral
component of training of health care
professionals. Multi-professional training
modules should be updated to enhance 
the skills of all health care professionals for
collecting BPMH.
The WHO Patient safety curriculum guide
developed initially for medical schools and 
then as a multi-professional curriculum (39, 63),
addresses safe medication use, collecting
complete medication histories, in addition to
addressing essential topics such as: human
factors, teamwork, managing clinical risk,
engaging with patients, families and caregivers,
and learning from errors. Both versions of the
Curriculum Guide have had positive evaluations
(64, 65) and have been found to be readily
usable and comprehensive. 
Educational interventions to improve medication
reconciliation performance specifically have
been examined in a systematic review. Varying
success was achieved with medication
reconciliation education interventions 
for students completing internal medicine
clerkships or among residents. Improved
competence and confidence was demonstrated
in some studies, while others noted minimal
effect (66). More work is needed to determine
successful components of educational
interventions.
Medication reconciliation toolkits and
resources
Health care leaders wishing to implement
programmes to improve medication safety 
can learn from a wide selection of initiatives,
many of which provide useful tips, toolkits 
and guidance, as described below.
WHO Patient Safety Solutions Project. As a
part of its collaboration, WHO issued brief
guidance with the former WHO Collaborating
Centre for Patient Safety Solutions on Assuring
medication accuracy at transitions in care
in 2007 as a “patient safety solution” (67).
WHO High 5s Project. The project – Assuring
medication accuracy at transitions in care:
medication reconciliation (8) – standardized
recommendations and implementation 
of medication reconciliation in a number of
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countries. An interim analysis of the WHO High
5s Project concluded that standardization was
feasible and the project had a positive impact
on reducing medication discrepancies in some
hospitals as well as other positive effects,
including improved teamwork and safety
culture (68). The toolkit includes a factsheet, 
a standard operating protocol and an
implementation guide (69).
The Institute of Healthcare Improvement.
The Institute of Healthcare Improvement has
included medication reconciliation in quality
improvement campaigns since the 100,000
Lives Campaign in 2005–2006, with many
hospitals, health systems and collaboratives
achieving admirable improvements (70).
Resources, including the How-to guide: prevent
adverse drug events (medication reconciliation)
are available online (71, 72). 
The National Institute for Health and Care
Excellence, National Patient Safety Agency.
The guidance, issued in 2007, recommends
having pharmacists involved in medication
reconciliation as soon as possible after
admitting an adult inpatient to hospitals in
England and Wales (73). It was supported 
by auditing and cost calculation tool.
The National Institute for Health and Care
Excellence medication optimization guidance.
The guidance includes recommendations on
medication-related communication systems
across transitions of care and medication
reconciliation. It broadens the responsibility 
for all health care providers to share complete
and accurate information about medication 
and reconcile medication within 24 hours of 
all transfers, and recommends discussing
medication with patients and giving them 
a complete and accurate list of their current
medication including any changes made during
their stay prior to discharge (74).
Medication at Transitions and Clinical
Handoffs. Gleason et al. in collaboration 
with the Agency for Healthcare Research 
and Quality produced a comprehensive toolkit
that can aid medication reconciliation
improvement programmes. It guides users
through a project management and process
redesign approach and includes tips for
conducting a patient interview, and information
on metrics and the process of auditing to
assess the process of the improvement
programmes (37).
Canadian Patient Safety Institute, Institute 
for Safe Medication Practices Canada and
Accreditation Canada. Collaboration between
these organizations and other partners aids
progress in medication reconciliation and
patient support (75). Various resources are
available including getting-started kits for acute
care, long-term care and home care. The
information kits include guides to medication
history taking, building a BPMH, forms and
formats of electronic systems, and information
about quality improvement and measurement
(76, 77).
Many other countries and health care
organizations have introduced various models,
including integrated medication management
and medication reconciliation solutions, with
good results. For example, optimizing the
medication use process in a comprehensive
way has reduced morbidity, mortality, length 
of stay, readmission and medication
administration error rate, and has improved
medication appropriateness and
communication across primary and secondary
care interfaces (8, 38). A number of other useful
resources are available for which references
are provided (78–83).
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3.3 Improvement in information
quality and availability across
transitions
Electronic systems can greatly facilitate
seamless transfer of information, reduce
transcription and decrease discrepancies at
transitions of care.
Reliable information sources
Any single source of information, whether
verbal, on paper or electronic, is a starting point
for compiling a BPMH, and the most reliable
sources should be combined with patient
interview to compile the BPMH. Defining which
sources are available and which are most
reliable requires local evaluation. 
The agreement of information sources with the
BPMH, compiled from patient interview and
information from all available sources, was
evaluated for patients admitted through an
emergency department in two Irish hospitals.
This study by Grimes et al. found nursing home
communication to be the most accurate source
of information on what medications patients
were actually using, followed by information
from a national dispensing record database.
The completeness of information was limited in
many of the information sources for patient’s
medication, which highlights the need to carry
out the full process to obtain a BPMH, including
patient interview, rather than relying on a single
information source (84).
Electronic health records
Electronic health records (EHRs) are in
increasing use globally. Many are single-site
EHRs, or confined to inpatient records only. 
To optimize medication safety at transitions,
EHRs or summary care records need to reflect
the patient’s medication usage across
transitions, be accessible both to patients 
and to treating health care professionals, and
be editable by all appropriate parties to ensure
its completeness and accuracy.
A meta-analysis reported a 45% reduction in
the proportion of medications with unintentional
discrepancies with medication reconciliation
supported by an electronic tool. It minimized
particularly omission of medications (85).
In addition, a systematic review of electronic
tools to support medication reconciliation
concluded that successful implementation of
EHR required favourable context, well designed
tools and attention to implementation features.
Evaluations generally focused on usability,
adherence and user satisfaction, with only one
randomized controlled trial evaluating the effect
on potential adverse drug events (86). 
Patients with access to EHR portals were 
found to have less visits, improved
communication, optimal changes in their
medication regime and improved adherence 
to treatment, however no consistent effect on
health outcomes was identified (87).
During the transition from primary care to
secondary care the availability of EHR could
enable pre-admission medication list to be
viewed, confirmed with the patient, adjusted 
if necessary, and thus confirmed as the BPMH.
Inpatient prescribing changes can then be
introduced, either incorporated into the EHR 
or separately to the main record. On discharge,
the BPMH should be referred to, with each
medication confirmed as continuing, changed
or discontinued and why. If any additional
medications are prescribed, discharge
prescription should be prepared that contains 
a full current medication list, with complete
information including changes that occurred 
in hospital and rationale for them. Many
countries have achieved considerable
advances in improving medication information
quality and availability across transitions of 
care (88–92). This highlights the possibilities
that EHR could have on safety of care during
points of transition.
Tools and technology to facilitate
medication reconciliation
Forms and checklists. Prompts or checklists
can aid staff to perform all stages of complex
processes. These can be in paper form or
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converted to simple electronic forms, such as
discharge communication requiring changes 
or discontinuations to be indicated and the
reasons for them (37, 38).
Information technology systems. Systems to
facilitate medication reconciliation processes
can improve safety and efficiency, and can be
relatively inexpensive to develop and
implement. A simple electronic system 
where discharge medication was entered in
predefined fields, which then populated both
the discharge prescription and summary, 
was demonstrated to be protective against
non-reconciliation compared to handwritten
discharges in Ireland. The electronic system
has since been enhanced so that the BPMH 
is entered on or after admission (93). At
discharge, each medication is communicated
as continued, changed (with a required reason),
discontinued (with a required reason), or
added.
Hospital computerized physician order entry
systems and EHR can facilitate streamlined
production of a more accurate and complete
discharge summary and prescription (94).
Meta-analyses have found that medication
reconciliation supported by an electronic tool
minimized unintended discrepancies at
transitions (85, 95).
3.4 Discharge and post-discharge
interventions 
In order to ensure patient safety during and
after discharge several interventions have been
developed. These interventions vary in level of
commitment, the involved health care provider




• electronic tools to facilitate information
transfer to health care professionals 
and patients
• shared involvement in follow-up by hospital
and community care providers, including
nurses, general practitioners and 
pharmacists 
• web-based access to discharge information
for general practitioners
• discharge letter shared with health care
providers
• patient education and counselling at
discharge and post-discharged.
The efficacy of these interventions in terms 
of improving post-discharge health outcomes 
is currently indefinite. A systematic review 
on improving patient handover from hospital 
to primary care, showed that various
interventions, such as specific discharge
programmes or comprehensive post-discharge
follow-up, had positive effects on patient care,
however the evidence is limited due to
heterogeneity and the complexity of the
interventions (96). Additionally, two systematic
reviews analysing community pharmacists’ 
role in transitions of care (97) and patient
education and counselling (98) as an
intervention around discharge shared similar
conclusions. Studies on specific interventions
to reduce patient harm at discharge were also
conducted, mainly on the effects of medication
reconciliation and medication review. Although
there is evidence for both interventions, more
research is required (9, 99, 100).
The main limitations with current evidence 
on the efficacy of interventions to improve
health outcomes around discharge are the
large heterogeneity, study characteristics 
and localized setting (58, 96, 98). In addition,
the clinical outcomes used to determine the
efficacy of discharge interventions would 
need to be standardized to allow better
comparability. Interventions reducing patient
harm around discharge would preferably be
multifaceted medication programmes,
combining active counselling and medication
reviews to attain safe discharge (101).
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3.5 The economic case 
Admissions associated with an adverse drug
reaction had a median inpatient stay of eight
days and accounted for 4% of the hospital bed
capacity in an English study. The projected
annual cost was £466 million to the National
Health Service (22).
Investments in staffing to improve medication
reconciliation processes have consistently
been found to produce a return exceeding
investment, due to shorter lengths of stay,
reduction in patient harm and reduction in
wastage of resources (8, 102, 103). In order 
to justify the cost–benefit, modelling may be
required to gain the support of health care
leaders and other stakeholders. Two models
are available as examples, these were created
to justify improved or newly designed
medication reconciliation implementation (37).
Research from many countries has
demonstrated a positive economic impact 
of introducing medication reconciliation (102,
104, 105). A return on investment (particularly 
in pharmacy staffing) of £5–£8 was achieved 
for each £1 invested (104). Pharmacist-led
medication reconciliation was one of only four
strategies for improving patient safety judged
to be economically attractive according to 
a systematic review by Etchells et al. (60).
It is necessary to design measure and
continuously improve any system or
interventions to reduce patient harm arising 
at transitions. This ensures that systems and
interventions achieve the maximum effect, 
are efficient and reduce unnecessary use of
resources. The economic case for medication
reconciliation should be built by medication
safety experts alongside health economists 
to advocate to policy makers for investing
resources in medication reconciliation,
particularly in LMICs.
3.6 Challenges
Achieving medication safety in transitions 
of care is complex. Some of key challenges
that need to be addressed include:
• recognition of the ubiquity and seriousness 
of the problem by health care leaders,
providers, professionals and patients;
• leadership commitment to sustained
improvement, with long-term planning, and
strategic and operational implementation;
• need for coordination between and within
primary and secondary health care settings,
with communication, collaboration and
information sharing;
• resource availability, including (a) health care
professional staffing, (b) clinical pharmacy
staffing, (c) access to high quality medication
information, and (d) IT support;
• cultural, organizational and professional
barriers to collaboration, communication and
integration between health care professional
groups, health care organizations and health
care professionals and patients;
• patient understanding about how to use
medication safely; and
• education, training and availability of tools
and systems to support patients and health
care professionals.
Obtaining the BPMH and reconciling
medication on admission to hospital is 
resource intensive, taking 15 to 30 minutes 
per intervention. More time may be required 
if medication review, patient discharge
counselling or other services are included.
Certain patient groups might be at higher risk
(e.g. patients with cognitive impairment or
limited health literacy) for medication-related
harm during transitions if not supported
sufficiently (37). 
Limitations in workforce capacity and capability
are a frequent barrier to improving medication
safety at transitions, despite evidence that
there is a return on investment that exceeds
expenditure. Planning for and investing in the
future health care workforce capacity, capability
and skills mix, in all health care settings, is a
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crucial component of achieving medication
safety at transitions. Multiple studies have
shown that there is a recognized benefit 
for clinical pharmacists in supporting rational
medication therapy by doctors and nurses
(106–108). A recent study from Sri Lanka
demonstrated that ward-based clinical
pharmacy services reduced the frequency 
of medication-related problems and
readmissions significantly for patients with 
non-communicable diseases (109). 
Solutions to improve medication safety at
transitions of care are likely to be influenced by
different national contexts. A WHO monograph,
Transitions of care: technical series on safer
primary care, identified some potential
solutions and success factors in providing 
safer transitions of care (38). The publication
listed organizational culture as one of the most
important factors in improving transitions 
of care. Research is needed to define common
pathways of care in countries where health
infrastructure and access is limited; map
transition points where medication interfaces
occur and reconciliation can fail; and develop
and evaluate interventions to improve
medication safety at transitions. 
In addition, IT can also contribute to medication
safety at transitions for instance, by facilitating
access to information and reducing transcribing
errors (110). However, these solutions can be
expensive and complex and may require both
capital and human resources to develop, test,
and continuously improve systems. The
increasing availability of open platforms and
portals however is making this potentially 
more achievable in economic terms.
Challenges are also experienced with data
protection and governance, developing reliable
data dictionaries, interoperability of different
systems, enabling access for patients, health
care professionals and different health care
providers, messaging between systems and 
the procurement process.
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What needs to be done4
Each country participating in the third WHO
Global Patient Safety Challenge: Medication
Without Harm is urged to take early priority
action to improve medication safety in
transitions of care.
4.1 Leadership commitment 
and planning
Health care leaders and providers would need
to understand and acknowledge the ubiquity
and seriousness of the problem (8, 37). The
following actions need to be undertaken in the
area of leadership commitment and planning to
develop improvement programmes for reducing
medication-related harm at transitions of care:
• develop collaboration with key stakeholders
and define clear goals;
• develop a long-term strategy to achieve 
the goals and put in place governance
arrangements to oversee implementation 
and progress;
• identify and allocate sufficient resources,
both in workforce and IT, to deliver the goals
in the short, medium and longer term;
• invest in research to inform understanding 
of problems and solutions, particularly 
where health care contexts differ from those
studied to date;
• plan, adapt, support and monitor the
improvement programmes; and
• develop mechanisms for education and
training for health care professionals and
patients.
4.2 Improvement programmes
It is central to agree on goals and measures 
to make sure staff and patients are engaged 
in the process of achieving safer transitions 
of care. Quality improvement methods should
be tested and tailored to the local situations
before implementation. The improvement
programmes should incorporate the key
elements of patient empowerment, medication
reconciliation and access to quality information.
Measurement should track whether changes
are resulting in the desired improvements.
Examples of resources and toolkits for
medication reconciliation are detailed in 
section 3.2.
4.3 Partnering with patients,  
families and caregivers
The patient is the one constant through all 
of their health care transitions and should be
recognized as the key stakeholders in their
health care (8). Countries are encouraged 
to build upon the motivation and passion of
patients and the public, to ensure medication
safety, and engage patients and the public 
in all stages of improvement programmes.
Extra support may be considered for patients
for whom health, social, financial or cultural
barriers may make safe transitions of care 
more challenging.
Proposed strategies to be implemented 
to engage patients, families and caregivers
include:
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• keeping a complete, up-to-date list of all
medications, in paper or electronic form,
including traditional, complementary and
over-the-counter medicines;
• understanding the benefits and risks of 
their medications and to engage with
healthcare professionals to agree which
medications they will take;
• understanding how to use each medication,
facilitated by dispensing labels, patient
information materials, tools and records 
to improve medication literacy;
• be involved in the planning, design, delivery
and monitoring of improvement initiatives 
(co-production); and
• identifying and reporting medication errors
and adverse drug events.
4.4 Medication reconciliation
Implementing formal structured processes 
for building the BPMH, reconciling medication
and supporting safe use of medication at all
transition points can deliver positive patient
outcomes. 
Roles and responsibilities of health care
professionals should be clearly defined,
adequate financial and technical resources
provided as well as support systems be
established (including IT) to ensure effective
medication reconciliation processes take 
place at every transition point (8). Health care
professionals involved in the reconciliation
processes should receive appropriate
competency-based education and training
to ensure medication safety at transitions 
of care.
BPMH and reconciling medication on
admission should be carried out by the
following steps (8):
• interviewing the patient, family or caregivers
in a structured format designed to elicit
information about all medications; 
• verifying the information given by the patient,
family or caregiver against at least one
reliable source of information before returning
to the patient and confirming the list of
medications; 
• reconciling the BPMH with the current
admission prescription to identify and resolve
any discrepancies; and
• sharing the final medication list with the
patient and other health care professionals.
Reconciling and communicating medication
changes on discharge involves:
• retrieving the BPMH on admission (or
determining this if it wasn’t completed on
admission);
• defining the final medication list at the time of
discharge or transfer; 
• deciding which medication is required after
discharge or transfer and prescribing or
listing it; and
• noting reasons for changes or
discontinuations to medication during the
admission and updating records to indicate
the discharge list and changes.
It is also important to make tools, checklists
and forms available to act as reminders and
forcing functions (see Annex 1) to complete
these processes (37). Examples include a
separate section on discharge documentation
to indicate changes in medication on the time
of admission; BPMH or medication
reconciliation shared record; and cards,
posters or tools highlighting the steps for
medication reconciliation process.
Targeting medication reconciliation
interventions to high-risk patients, including
older persons, those on high number of
medications, on high-risk medications or with
morbidities such as renal impairment, may be
of highest yield (38, 54, 59). 
4.5 Information quality and
availability at all care transitions
Information to build the BPMH
Patients and health care professionals should
have access to high-quality, up-to-date patient
medication list information to aid seamless
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transitions, for example:
• patient-held medication records, medication
lists or medication passports, in paper or
mobile app form;
• simple IT systems to facilitate or streamline
medication reconciliation; and
• EHRs. 
Communication and coordination should be
improved between hospitals (public and
private), the community (general practitioner,
pharmacist and other health care providers),
residential care, patients, and families or
caregivers, including ensuring IT
interoperability. 
Information to support safe medication use
Health care professionals and patients should
be ensured access to high-quality, up-to-date
general medication information. National
medication authorities, regulators,
pharmacovigilance centres or patient safety
agencies can support provision of accessible
information for patients to understand and use
medication effectively and safely. Access to
such information will help health care
professionals to identify medication (for
example, through a database for identification
of tablets and capsules) and to store, prescribe,
dispense and administer safely. Medication
information services can provide a valuable
query-answering service within hospitals and 
to health care professionals and patients. 
Confusion and medication error, including
discrepancies at transitions, could be reduced
by naming, packaging and labelling of
medication that communicates the key
information prominently (including name,
strength, and form) and ensuring medication
information is readily accessible to and usable
by patients and health care professionals.
Use of the international nonproprietary name
(INN) should be promoted to improve clarity
and understanding for both patients and health
care professionals. Patients and health care
professionals also need to understand the
limited situations (for example, some modified
release or low therapeutic index medication
such as antiepileptic medication) in which a
specific brand should be used and not
substituted. Understanding can be aided by
ensuring the prominence of the INN in
packaging, labelling and product information.
4.6 Building capacity of health care
professionals
Improvement in medication practices across
transitions of care requires health care
professionals who are informed and educated
about:
• the problem of unsafe medication practices
and medication errors and their impact, 
while being motivated to lead and advocate
implementation of appropriate measures 
with decision makers;
• how to address the problem, including
obtaining a BPMH, when, by whom and 
how to carry out medication reconciliation,
and how to communicate changes to other
health care providers;
• considering patients as partners who need 
to be involved in decisions about their
medication and who need to understand 
and agree with medication plans, and
supported with training and tools to do so;
• collaborating in multidisciplinary
environments, with roles and responsibilities
clearly defined and working to maximize
medication safety for patients at transitions;
and
• working within systems and processes that
support safe practice, with streamlined and
better information, medication reconciliation
and patient support. 
These elements should be incorporated into
undergraduate, postgraduate and continuing
professional development curricula for all
professionals involved in medication-related
processes. Performance should be evaluated
and feedback given, within the professional’s
work structure and as part of formal
credentialing and professional appraisal. 
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4.7 Monitoring and measurement
Monitoring and measurement are a crucial 
part of improving healthcare processes (8).
Data and insight from measurement can enable
health care leaders to monitor performance 
in transitions of care and to evaluate whether
changes designed to facilitate medication
safety in transitions of care translate to
meaningful reductions in discrepancies and
patient harm (38). 
In improvement programmes, goals are defined
and samples are measured over time to
determine if progress is being made towards
the desired goals, if performance is showing
normal variation or if there is deterioration. 
This is measurement for improvement, not
research or judgement (111). Both process and
outcome measures should be tracked to give 
a realistic evaluation of the quality of transitions
of care performance (8, 72). Where possible,
measurement should be embedded into routine
processes or quality assurance systems and
existing data sets should be used to minimize
workload. If specific measurements are
required, small sequential samples can be
taken and run charts or control charts may be
used to track and interpret data over time.
Institute for Healthcare Improvement provides
further guidance on this in their quality
improvement toolkit (112).
Some suggested measures are presented below.
1. Outstanding unintentional medication discrepancies 
This process measure helps to verify the overall quality and effectiveness of the medication history
and reconciliation processes (8) at any point of transition. This measure can be assessed using
multiple indicators. A few indicators from the WHO High 5s Project (8) have been adapted to assess
any point of transition. These adapted measures are presented below.
Percentage of patients with at least one outstanding unintentional discrepancy
= Number of patients with at least one outstanding unintentional discrepancy x 100
Number of eligible* patients
Mean number of outstanding unintentional medication
discrepancies per patient
= Number of outstanding unintentional discrepancies
Number of eligible* patients
2. Percentage of patients receiving medication reconciliation 
This is a process measure that tracks the extent to which medication reconciliations are performed
(8), at any point of transition. This should be used in combination with other types of measures to
track the safety of transitions of care. One indicator from the WHO High 5s project has been adapted
to assess any point of transition. This adapted measure is presented below.
Percentage of patients receiving medication reconciliation 
= Number of eligible* patients receiving medication reconciliation x 100
Number of eligible* patients admitted
* Eligibility may be adjusted depending on country and hospital context. All inpatients is recommended unless
decisions have been made to focus improvement efforts and measurement on specific patient groups. 
* Eligibility may be adjusted depending on country and hospital context. All inpatients is recommended unless
decisions have been made to focus improvement efforts and measurement on specific patient groups. A random
sample of at least 30 patients is recommended by the WHO High 5s Project (8).
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3. Patient-centred measures
Patient and family engagement is considered as one of the foundations for safe, quality transitions of
care (113). Periodic assessments of patient experience and understanding could be considered to
monitor the effectiveness of programmes, using validated patient survey instruments (38, 114).
Patient surveys can consist of a variety of questions to assess the transitions of care – one example
from Ireland is displayed below. Further medication safety related survey questions, which have
been used in Canada (115) and England (116, 117) are also available. In addition to patient surveys,
patient and provider stories and experiences can also provide important perspectives to improve
patient-centred measures (118).
Did a member of staff explain the purpose of the medicines you were to take at home 
in a way you could understand?
Yes, completely
Yes, to some extent
No
I did not need an explanation
I had no medicines
4. Measuring medication-related harm arising at transitions of care
Measuring the prevalence of medication-related harm associated with transition of care is
indispensable to understand whether the interventions to make processes safer are effective. To
build empirical evidence on medication-related harm arising at transition of care, it is needed to have
robust research methodology and periodic collection of data. Quantifying this harm is also significant
for justifying rationale for investment in resources to implement medication safety interventions.
Other sources of information relating to medication safety at transitions of care may also be analysed
to inform improvement efforts, e.g. patient safety incident and near miss reports (see Annex 1),
patient, family, caregivers and staff complaints, pharmacovigilance reports, claims, and morbidity
and mortality reviews. The rich information available from these sources should be considered
qualitative and used to complement the quantitative measures suggested above, for example to
obtain patient stories associated with transitions. However, they should not be used to measure the
prevalence or incidence of harm.
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Conclusions 5
Unintended medication discrepancies 
affect nearly every patient that moves across
transitions of care. WHO urges countries 
to commit to prioritizing effective action 
for improving medication safety in transitions 
of care.
Information from global research and
innovation is shared in this report, with the
objective of facilitating those initiating or
enhancing existing programmes to improve
medication safety in transitions of care.
Meeting the complex challenge of reducing
medication-related harm arising at transitions
requires long-term leadership commitment,
coordination and collaboration, formulation 
of goals and strategies, and investment 
of resources. Improvement programmes 
are needed to meet the goals. Key elements 
of programmes include implementing formal
structured processes with enhanced workforce
capacity and capability to deliver medication
reconciliation at transitions, partnering with
patients and families, improving information
quality and availability, in particular a patient-
held medication record or medication passport,
and measurement.
Prioritizing this area for early and sustained
action over the next five years will contribute 
to achieving the goal of the third WHO Global
Patient Safety Challenge: Medication Without
Harm – which is to reduce severe, avoidable
medication-related harm by 50% globally.
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Any injury resulting from medical interventions related to a drug. This includes
both adverse drug reactions in which no error occurred and complications
resulting from medication errors (1)
A response to a drug which is noxious and unintended and that occurs at doses
used in humans for prophylaxis, diagnosis or therapy of diseases, or for the
modification of physiological function (2). These are often classified as two types:
Type A and Type B (3)
Type A adverse drug reaction
An augmented pharmacologically predictable reaction which is dose
dependent. It is generally associated with high morbidity and low mortality (4)
Type B adverse drug reaction
A bizarre reaction which is unpredictable pharmacologically and is independent 
of dose. It is generally associated with low morbidity and high mortality (4)
A severe, life-threatening systemic hypersensitivity reaction characterized by
being rapid in onset with potentially life-threatening airway, breathing, or
circulatory problems and is usually, although not always, associated with skin 
and mucosal changes (5)
A medication history obtained by a clinician which includes a thorough history 
of all regular medication use (prescribed and non-prescribed), using a number 
of different sources of information (6)
The process of tapering, stopping, discontinuing, or withdrawing drugs, with 
the goal of managing polypharmacy and improving outcomes (7)
Essential medicines are those that satisfy the priority health care needs of the
population (8)
An aspect of a design that prevents the user from taking an action without
consciously considering information relevant to that action. It forces conscious
attention upon something (“bringing to consciousness”) and thus deliberately
disrupts the efficient or automatized performance of a task (9)
A list of medicines, usually by their generic names, and indications for their use. 
A formulary is intended to include a sufficient range of medicines to enable
medical practitioners, dentists and, as appropriate, other practitioners to prescribe
all medically appropriate treatment for all reasonably common illnesses (10)
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Drugs that bear a heightened risk of causing significant patient harm when they
are used in error. Although mistakes may or may not be more common with these
medications, the consequences of an error are clearly more devastating to
patients (11)
The degree to which use of medication by the patient corresponds with the
prescribed regimen (12)
Any difference between the medication use history and the admission medication
orders (13). Discrepancies may be intentional, undocumented intentional or
unintentional discrepancies (6)
Any preventable event that may cause or lead to inappropriate medication use or
patient harm while the medication is in the control of the health care professional,
patient, or consumer (14)
The formal process in which health care professionals partner with patients to
ensure accurate and complete medication information transfer at interfaces of
care (6)
Patient harm related to medication. It includes preventable adverse drug events
(e.g. due to a medication error or accidental or intentional misuse) and non-
preventable adverse drug events (e.g. an adverse drug reaction)
A structured evaluation of patient’s medicines with the aim of optimizing
medicines use and improving health outcomes. This entails detecting drug related
problems and recommending interventions (15)
Freedom from accidental injury during the course of medication use; activities to
avoid, prevent, or correct adverse drug events which may result from the use of
medications (16)
The multistep process in the use of medications by or for patients, including:
prescribing, ordering, storage, dispensing, preparation, administration and/or
monitoring
Ensuring that the right patients get the right choice of medicine, at the right time.
By focusing on patients and their experiences, the goal is to help patients to (a)
improve their outcomes; (b) take their medicines correctly; (c) avoid taking
unnecessary medicines; (d) reduce wastage of medicines; and (e) improve
medicines safety (17)
The presence of two or more long-term health conditions, which can include (a)
defined physical and mental health conditions such as diabetes or schizophrenia;
(b) ongoing conditions such as learning disability; (c) symptom complexes such as
frailty or chronic pain; (d) sensory impairment such as sight or hearing loss; and
(e) alcohol and substance misuse (18)
An incident that did not reach the patient (19)
The absence of preventable harm to a patient and reduction of risk of
unnecessary harm associated with health care to an acceptable minimum. An
acceptable minimum refers to the collective notions of given current knowledge,
resources available and the context in which care was delivered weighed against
the risk of non-treatment or other treatment (20)
Science and activities relating to the detection, assessment, understanding and
prevention of adverse effects or any other drug-related problem (2)
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Polypharmacy is the concurrent use of multiple medications. Although there
is no standard definition, polypharmacy is often defined as the routine use 
of five or more medications (21). This includes over-the-counter, prescription
and/or traditional and complementary medicines used by a patient
Medications with ineffectiveness or high risk–benefit ratio for a particular
individual or group of individuals (22)
The reduction of risk of unnecessary harm to an acceptable minimum (19)
A known effect, other than that primarily intended, related to the
pharmacological properties of a medication (19)
The various points where a patient moves to, or returns from, a particular
physical location or makes contact with a health care professional for the
purposes of receiving health care (23)
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